5AM Venture Exits MoonLake Following a Challenging Year: Key Highlights to Note
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 18 2025
0mins
Source: Fool
5AM Venture Management's Exit: On November 14, 2025, 5AM Venture Management, LLC sold its entire stake in MoonLake Immunotherapeutics, liquidating 282,313 shares for an estimated value of $13.33 million, marking a significant reduction in its reportable assets.
Stock Performance: Following the sale, MoonLake's shares were priced at $13.58, reflecting a 74.9% decline over the past year and underperforming the S&P 500 by 88 percentage points, indicating a challenging market environment for the company.
Risk Management Strategy: The decision to fully exit the investment is seen as a move to mitigate risk amid the stock's poor performance, suggesting a shift towards more stable investments rather than remaining in a volatile clinical-stage company.
Long-term Outlook: MoonLake's future hinges on the success of its main drug, sonelokimab, with investor sentiment likely to fluctuate based on clinical trial results, emphasizing the importance of monitoring the company's development milestones.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TRDA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TRDA
Wall Street analysts forecast TRDA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TRDA is 16.50 USD with a low forecast of 13.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 11.660
Low
13.00
Averages
16.50
High
20.00
Current: 11.660
Low
13.00
Averages
16.50
High
20.00
About TRDA
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in establishing a class of medicines, which engages intracellular targets. Its Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. The Company is advancing a robust development portfolio of RNA-, antibody- and enzyme-based programs for the potential treatment of neuromuscular, ocular, metabolic and immunological diseases, among others. It is engaged in preclinical lead optimization efforts in both neuromuscular and non-neuromuscular disease and discovery efforts to advance platform applications. Its lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne who are exon 44, 45, 50 and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Entrada Therapeutics CEO Dipal Doshi to Present at 2026 J.P. Morgan Healthcare Conference
- Conference Presentation: Entrada Therapeutics CEO Dipal Doshi is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, showcasing the company's latest advancements in biopharmaceuticals, which is expected to attract investor and industry attention.
- Webcast Availability: The presentation will be live-streamed on Entrada's Investor Relations website and will be archived for 30 days post-event, ensuring that investors who cannot attend in real-time can access key information, thereby enhancing the company's transparency.
- Company Background: Entrada Therapeutics is a clinical-stage biopharmaceutical company focused on developing Endosomal Escape Vehicle (EEV™) therapeutics that enable efficient delivery of treatments, aiming to improve therapeutic indices and provide potential solutions for neuromuscular and ocular diseases, highlighting its strategic positioning in innovative drug development.
- R&D Project Progress: The company is advancing its lead oligonucleotide programs for Duchenne muscular dystrophy and is collaborating on a clinical-stage program, VX-670, for myotonic dystrophy type 1, indicating its deep commitment and market potential in specific disease areas.
Continue Reading
Entrada Therapeutics CEO Dipal Doshi to Present at 2026 J.P. Morgan Healthcare Conference
- Conference Presentation: Entrada Therapeutics CEO Dipal Doshi will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, which is expected to attract investor attention and enhance the company's visibility.
- Live Webcast: The presentation will be available via live webcast on Entrada's Investor Relations website, with a replay accessible for 30 days post-event, aimed at increasing engagement and transparency with potential investors.
- Company Overview: Entrada Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neuromuscular and ocular diseases, showcasing its cutting-edge position in the biopharmaceutical sector.
- Product Development: The company is advancing a robust portfolio of RNA and protein-based programs, particularly targeting treatments for Duchenne muscular dystrophy, indicating its potential in addressing challenging diseases.
Continue Reading